Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT2 inhibitor initiation with reduced versus usual furosemide dosing in heart failure
MOH_2024-01-02_013155Phase 4Not yet recruiting
- Sponsor
- אורן כספי
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of empagliflozin, dapagliflozin and furosemide in heart failure (HF) (2 arms), sponsored by אורן כספי. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
empagliflozindapagliflozinfurosemide
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on MOH_2024-01-02_013155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-01-02_013155.